Shares of Johnson & Johnson (NYSE:JNJ) have been given an average rating of “Hold” by the twenty-three analysts that are covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $134.72.
Several research analysts have commented on JNJ shares. Royal Bank Of Canada reaffirmed a “buy” rating and set a $138.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 12th. BidaskClub lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 1st. UBS AG reaffirmed a “buy” rating and set a $148.00 price objective (up from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $148.00 price objective for the company in a research note on Thursday, July 27th. Finally, Credit Suisse Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Friday, August 4th.
Johnson & Johnson (NYSE:JNJ) traded up 3.43% during midday trading on Thursday, reaching $140.79. 11,717,122 shares of the company were exchanged. The company has a 50-day moving average of $132.57 and a 200 day moving average of $130.27. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $141.12. The firm has a market capitalization of $377.88 billion, a PE ratio of 23.82 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. Johnson & Johnson’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.68 earnings per share. Equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.
A number of institutional investors have recently made changes to their positions in JNJ. Harding Loevner LP bought a new position in Johnson & Johnson in the second quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. increased its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares in the last quarter. IHT Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson during the second quarter valued at about $124,000. Institutional investors and hedge funds own 65.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Receives $134.76 Average Price Target from Brokerages” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/10/26/johnson-johnson-jnj-receives-134-76-average-price-target-from-brokerages.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.